![The sights of Avalon Air Show 2025: Day Three [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/03/f-35-avalon-final-day-scaled-e1743079275404.jpg?#)
.jpg)
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure global rights to a preclinical prospect that paired well with its GLP-1 blockbuster semaglutide in mice.
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure global rights to a preclinical prospect that paired well with its GLP-1 blockbuster semaglutide in mice.
